The Food and Drug Administration on Thursday approved the Autus Size-Adjustable Valve, a surgically implanted pulmonary heart valve for children with congenital pulmonary valve disease, and it is two firsts in one device. It is the first heart valve designed to be widened after surgery so it can keep pace with a child's growth, and the first valve the agency has approved in the United States that uses a polymer rather than animal tissue for its leaflets, the flaps inside the valve that open and close. The approval went to Edwards Lifesciences, which acquired the valve's developer, Autus Valve Technologies, earlier this year.

The device arrives at a problem pediatric cardiologists have managed the same way for decades, and the approval's fine print is as interesting as its headline. The company's support for the design leans heavily on a 62-patient pivotal study with six-month follow-up, while the peer-reviewed evidence for the concept comes from a first-in-human study of eleven children.

The timing problem the valve is built around

Congenital heart defects are among the most common birth defects in the United States, affecting about 1 in every 100 births. Two of them, pulmonary valve stenosis and pulmonary valve atresia, narrow or block the valve that lets blood leave the right side of the heart for the lungs. The FDA cites Centers for Disease Control and Prevention figures putting the two conditions together at around 4,200 babies a year in the United States.

Surgery can restore blood flow, but it often leaves a child with pulmonary regurgitation, meaning blood leaks back through the valve. Over time that can weaken or enlarge the right ventricle, and the child eventually needs the valve replaced. Replacement is available today. The problem is deciding when to do it. A child who receives a valve too early will outgrow it and need another operation, and each repeat open-heart surgery carries its own risk and its own recovery. Wait too long, and the right ventricle takes damage that may not reverse.

Michelle Tarver, who directs the agency's Center for Devices and Radiological Health, described the tradeoff in the approval announcement, saying the device gives doctors the option of far fewer trips to the operating room.

What the valve does, and what it is made of

The Autus valve goes in at roughly 13 millimeters in diameter, which is a size that fits a toddler or a preschool-aged child, and it can later be widened using a balloon catheter threaded to the valve without reopening the chest. The FDA says it can reach up to 22 millimeters, comparable to an adult-sized pulmonary valve. Edwards describes the same range for the continuing access study, which enrolls patients from 18 months to 16 years and follows them for ten years.

The leaflets are the other departure. Valves used in children today typically use tissue taken from animals, and that tissue tends to stiffen and break down faster in a growing child than in an adult, which shortens the interval before the next operation. The Autus valve uses a polymeric material instead. The agency said one-year follow-up data suggest the synthetic leaflets hold up over time, and it noted this is the first time it has approved a valve with polymeric leaflets for any indication.

What the pivotal study showed at six months

The approval rests on a single-arm clinical study that enrolled 62 pediatric patients at 12 sites in the United States. At the six-month follow-up, the agency said the first 60 patients showed acceptable hemodynamic performance, which means blood flow through the right side of the heart stayed within acceptable limits, with no more than mild leakage back through the valve.

Every procedure in the study was successful, and the agency reported no deaths, no blood clots that required additional treatment, and no strokes or other clot-related complications. The safety record was not spotless in the mechanical sense. Three patients had a fracture in the valve frame, and two had reduced movement of one of the leaflets. The agency said none of those events produced symptoms, and that valve performance began deteriorating in two patients who had started to outgrow the device. Both of those valves were expanded successfully without an invasive operation.

Six months is a short window for a device whose purpose is to last years. The agency said longer-term studies are underway to better understand those risks and to gather more data on whether repeated expansion keeps the valve working well enough to spare children additional surgery. In its own words, the experience with outgrown valves being expanded is limited.

The evidence that is still being collected

The strongest published evidence for the concept is not the pivotal study, because that study's results have not been fully published. It is the Early Feasibility Study, whose one-year outcomes appeared in the Journal of Thoracic and Cardiovascular Surgery.

That study enrolled eleven subjects, nine of them male, at three centers, with a median age at implant of 8.2 years and a range from 2.7 to 13.9 years. Every subject had the valve size-adjusted at implant, landing between 14 and 20 millimeters of internal diameter. The median hospital stay was four days. At one year there was no mortality, all eleven subjects were free of device-related adverse events, no thrombus was observed, and no subject developed endocarditis. The authors concluded that the one-year results showed intact valve function and no device-related adverse events, and noted the valve had moved into a pivotal Investigational Device Exemption study, which is the 62-patient trial the approval rests on.

Eleven children followed for a year cannot establish how a synthetic leaflet behaves over the decade a childhood valve is meant to serve, and the feasibility study's authors do not claim otherwise. The question the approval leaves open is durability, and the answer will come from patients who are enrolled now and followed for years.

The pivotal study has a second limitation that its size does not capture. It is a single-arm study, which means every child enrolled received the Autus valve and none received the tissue valve that is the current standard. There is no comparison group and therefore no head-to-head evidence about which device performs better in similar children. Single-arm designs are common in device trials where the condition is serious and randomizing a child to the older option is difficult to justify, and the agency accepts them when a device meets a prespecified performance goal drawn from what is already known about the alternative. The tradeoff is that the results establish that the valve worked, not that it works better.

What the agency decided is narrower than the approval's framing suggests. Under the premarket approval standard, the question is whether there is reasonable assurance that a device is safe and effective for its intended use and whether its benefits outweigh its known risks. The agency answered yes on both. It also wrote into its own announcement that experience with outgrown valves being expanded is limited and that longer-term studies are still collecting data, which is a way of saying that the approval reflects confidence in the design rather than proof about durability.

How the device reached the market

The Autus valve came to Edwards Lifesciences through an acquisition. The company bought Autus Valve Technologies in February for $128.9 million, according to trade coverage of the transaction, and the device was already inside FDA programs meant to speed up review of devices for serious conditions.

It received a Breakthrough Device designation, and it is the first pediatric approval to come out of the agency's Total Product Life Cycle Advisory Program, a voluntary program that gives device developers more interaction with the agency during development. The approval itself came through the premarket approval pathway, the agency's most stringent route for medical devices, used for Class III devices that generally carry the greatest risk. Before clearing the valve, the agency reviewed nonclinical and clinical data to determine whether there was reasonable assurance of safety and effectiveness and whether the benefits outweighed the known risks.

The device was already in use before the approval. In August, a team at C.S. Mott Children's Hospital, part of University of Michigan Health, performed the first United States implant under the study that lets children receive the valve while the agency reviews the pivotal results. The child was six years old. Jennifer Romano, the surgeon who led the procedure, said in a statement that the valve is a game changer and that the team may now be giving a child a valve that could last a lifetime.

The FDA's announcement frames the decision in political as well as clinical terms, describing the approval as reflecting the administration's commitment to bringing breakthrough technologies to market and quoting Acting Commissioner Kyle Diamantas calling it a historic turning point. That framing is the agency's own. What the review produced is a device with a documented six-month safety profile, a documented one-year profile in a much smaller group, and an obligation to keep collecting data.

What changes for families, and what does not

Approval means the valve can now be sold and implanted outside a clinical study, which converts a device that was available to a small number of children at selected centers into a standard commercial option. For parents whose child faces a pulmonary valve replacement, that adds a choice where the previous one was between a tissue valve that will wear out and another operation.

It does not change the fact that a size-adjustable valve still requires an operation to place. This is not a catheter procedure from the start, and a balloon expansion later is a smaller intervention than open-heart surgery but not a trivial one. It also does not settle the question that matters most to a family deciding between options, which is how long the valve will last in their child. The pivotal trial and the continuing access study both follow patients annually for up to a decade, and those results will take years to arrive.

One more limit belongs in the same sentence. The device was studied in children aged 18 months to 16 years with congenital pulmonary valve disease, in the pulmonary position only. Nothing in the approval record speaks to how it performs in adults, in another valve position, or in children younger than the study's youngest participant.

The approval also leaves the price unanswered. Edwards has not said what the valve will cost, and the relevant comparison is not a single number. A tissue valve that costs less up front can end up costing more across a childhood measured in operations, recovery time, and days out of school and work, while a device that avoids a second operation but fails earlier than expected produces the opposite arithmetic. That calculation will be made hospital by hospital and insurer by insurer, and the published trial data will not settle it.

Primary sources

  1. U.S. Food and Drug Administration, FDA Approves First Heart Valve Designed to Grow with Children, for the approval, the device specifications and materials, the pivotal study results at six months, the advisory program and premarket approval pathway, the statements of Acting Commissioner Kyle Diamantas and CDRH Director Michelle Tarver, and the CDC figures on pulmonary valve atresia and stenosis.
  2. Journal of Thoracic and Cardiovascular Surgery, Novel size-adjustable pulmonary valve US early feasibility study: One-year outcomes, for the eleven-subject first-in-human study, its enrollment and follow-up, the implant sizing, and the one-year safety results.
  3. Edwards Lifesciences, AUTUS size-adjustable valve clinical study, for the ongoing continued access study, its age range of 18 months to 16 years, and the ten-year follow-up schedule.
  4. Cardiovascular Business, This could be transformative: Surgeon performs first US implant of heart valve still under FDA review, for the Edwards Lifesciences acquisition of Autus Valve Technologies, the first United States implant at C.S. Mott Children's Hospital, and the statement of surgeon Jennifer Romano.